相关实验视频

Updated: Jun 23, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

癌症中LRP6的多方面影响:探索瘤发育,免疫调节和向疗法

Liangliang Li¹, Li Zhao^2,3, Jincai Yang⁴

¹Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, People's Republic of China.

Medical oncology (Northwood, London, England)

|June 19, 2024

概括

低密度脂蛋白受体相关蛋白6 (LRP6) 在癌症中起着复杂的作用,既起瘤基因作用,又起瘤抑制作用. 了解LRP6的功能和向它为新的癌症疗法提供了潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞信号传递细胞信号传递

背景情况:

低密度脂蛋白受体 (LDLR) 相关蛋白6 (LRP6) 是细胞表面受体,对Wnt/β-catenin信号传递至关重要.
这一途径影响细胞分化,迁移和新陈代谢.
在肝癌,结直肠癌和前列腺癌等癌症中,LRP6经常过度表达,通常促进瘤生长.

研究的目的:

审查LRP6在各种癌症中的多方面的作用.
探索LRP6与瘤微环境 (TME) 的相互作用.
讨论针对LRP6的癌症疗法.

主要方法:

对癌症中LRP6表达和功能研究的文献综述.
对LRP6参与规范Wnt/β-catenin和替代信号通路的分析.
检查LRP6对瘤透免疫细胞和TME的影响.

主要成果:

LRP6的作用是有争议的;它可以促进增殖,但在某些情况下也可以抑制转移.
虽然LRP6对瘤免疫和TME有影响,但这一点尚未得到充分理解.
LRP6与mTORC1,CXCL12/CXCR4和KRAS等通路相互作用,独立于Wnt信号传输.

结论:

在癌症的进展和转移中,LRP6具有复杂的,取决于背景的作用.
准LRP6并了解其TME相互作用是新型癌症治疗方法的有希望的途径.
需要进一步的研究才能充分阐明LRP6的功能和治疗潜力.

关键词:

癌症癌症癌症癌症临床应用临床应用低密度脂蛋白受体相关蛋白6 低密度脂蛋白受体相关蛋白一个角色,一个角色.瘤微环境是一个微环境.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...